Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138, Tesamorelin is FDA-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy and is studied for broader body-composition, NAFLD, and cognitive effects via GH/IGF-1 axis modulation1893.
While PEG-MGF works as a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138, Tesamorelin is a full-length 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that binds GHRHR, activating cAMP/PKA signaling to increase endogenous GH and IGF-1, with improved stability versus native GHRH182893102.
PEG-MGF
IGF1
Tesamorelin
GHRH
PEG-MGF and Tesamorelin are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Cardiovascular health contexts, while PEG-MGF is more of a signal peptide and Tesamorelin is better described as a hormone peptide and Metabolic peptide. Their biological logic is quite different: PEG-MGF is a growth factor mimetic and a signaling modulator, whereas Tesamorelin is a receptor agonist. Both are synthetic in origin and their development context also differs, with PEG-MGF in Preclinical development while Tesamorelin is approved. PEG-MGF carries pegylation features, while Tesamorelin instead reflects amidation changes, while their sequence patterns also diverge, with PEG-MGF showing protein-mimetic sequence features and Tesamorelin showing alpha-helical domain features.
No related articles are linked to these peptides yet.